SOHM Inc. (OTC:SHMN) Reveals Path-Breaking ABBIE Technology Update
The biotech and pharmaceutical firm SOHM Inc. (OTC:SHMN) could be the one to track this week in light of the latest announcement it made yesterday. In an announcement on Monday, the company revealed that pathbreaking findings had been made in relation to its proprietary ABBIE Technology. Let’s take a closer look.
Key Finding
In the news release, the Chief Operating Officer of the company, Dr. David Aguilar, stated that the updates were related to the development and eventual commercialization of the technology. The team involved with ABBIE had made significant progress and helped SOHM make the operations strategy significantly more refined and future-facing. The company revealed that it had decided against selling ABBIE kits for retail use, and instead the company was looking to work out a licensing model through the powerful support of SOHM’s fast-growing intellectual property portfolio.
Further Information
The company went on to add that the change in business strategy would also help it in putting greater focus on sales and marketing initiatives for creating strong licensing partnerships. The company was currently engaged in thorough technical diligence discussions with regards to the major pivot in the direction of ABBIE commercialization.
Technicals
| +/- EMA(20) | 0.0006 (-33.33%) |
| +/- SMA(50) | 0.0007 (-42.86%) |
| +/- SMA(200) | 0.001 (-60.00%) |
| 5-Day Perf. | -33.33% |
| 1-Month Perf. | -42.86% |
| 3-Month Perf. | -60% |
| 6-Month Perf. | -69.23% |
| YTD Perf. | -42.86% |
| 1-Year Perf. | -69.23% |
| RSI(14) | 31.09 |
| ATR(14) | – |
| ADX(14) | 26.26 |
| Beta (5Y) | 1.38 |